Literature DB >> 9593558

Prospective study of calcium channel blocker use, cardiovascular disease, and total mortality among hypertensive women: the Nurses' Health Study.

K B Michels1, B A Rosner, J E Manson, M J Stampfer, A M Walker, W C Willett, C H Hennekens.   

Abstract

BACKGROUND: In several observational studies, patients prescribed calcium channel blockers had higher risks of cardiovascular diseases and mortality than those prescribed other antihypertensive medications. We explored these associations in the Nurses' Health Study. METHODS AND
RESULTS: A total of 14 617 women who reported hypertension and regular use of diuretics, beta-blockers, calcium channel blockers, ACE inhibitors, or a combination in 1988 were included in the analyses. Cardiovascular events and deaths were ascertained through May 1, 1994. We documented 234 cases of myocardial infarction. Calcium channel blocker monodrug users had an age-adjusted relative risk (RR) of myocardial infarction of 2.36 (95% CI, 1.43 to 3.91) compared with those prescribed thiazide diuretics. Women prescribed calcium channel blockers had a higher prevalence of ischemic heart disease. After adjustment for these and other coronary risk factors, the RR was 1.64 (95% CI, 0.97 to 2.77). Comparing the use of any calcium channel blocker (monodrug and multidrug users) with that of any other antihypertensive agent, the adjusted RR was 1.42 (95% CI, 1.01 to 2.01). An association between calcium channel blocker use and myocardial infarction was apparent among women who had ever smoked cigarettes (covariate-adjusted RR, 1.81; 95% CI, 1.20 to 2.72) but not among never-smokers (RR, 0.94; 95% CI, 0.48 to 1.84).
CONCLUSIONS: In analyses adjusted only for age, we found a significant elevation in RR of total myocardial infarction among women who used calcium channel blockers compared with those who did not. After adjustment for comorbidity and other covariates, the RR was reduced. Whether the remaining observed elevated risk is real, or a result of residual confounding by indication, or chance, or a combination of the above cannot be evaluated with certainty on the basis of these observational data.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593558     DOI: 10.1161/01.cir.97.16.1540

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

Review 1.  Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes.

Authors:  N Chapman; B Neal
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

2.  [ALLHAT: Old Hat Hits All? On selection of the optimal antihypertensive drug].

Authors:  Jörg Slany
Journal:  Wien Klin Wochenschr       Date:  2003-03-31       Impact factor: 1.704

Review 3.  Understanding women's health through data development and data linkage: implications for research and policy.

Authors:  A Kazanjian
Journal:  CMAJ       Date:  1998-08-25       Impact factor: 8.262

Review 4.  The INSIGHT and NORDIL trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection?

Authors:  M C Ruddy
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

Review 5.  Pharmacological management of renal colic in the older patient.

Authors:  Blayne K Welk; Joel M H Teichman
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 6.  Hypertension treatment guidelines: is it time for an update?

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

7.  Do people with risky behaviours participate in biomedical cohort studies?

Authors:  Anne W Taylor; Eleonora Dal Grande; Tiffany Gill; Catherine R Chittleborough; David H Wilson; Robert J Adams; Janet F Grant; Patrick Phillips; Richard E Ruffin
Journal:  BMC Public Health       Date:  2006-01-23       Impact factor: 3.295

8.  The Association of Family History of Premature Cardiovascular Disease or Diabetes Mellitus on the Occurrence of Gestational Hypertensive Disease and Diabetes.

Authors:  Dong-Ju Choi; Chang-Hwan Yoon; Heesun Lee; So-Yeon Ahn; Kyung Joon Oh; Hyun-Young Park; Hea Young Lee; Myeong Chan Cho; Ick-Mo Chung; Mi-Seung Shin; Sung-Ji Park; Chi Young Shim; Seong Woo Han; In-Ho Chae
Journal:  PLoS One       Date:  2016-12-05       Impact factor: 3.240

9.  The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study.

Authors:  Inés Gómez-Acebo; Trinidad Dierssen-Sotos; Camilo Palazuelos; Beatriz Pérez-Gómez; Virginia Lope; Ignasi Tusquets; M Henar Alonso; Victor Moreno; Pilar Amiano; Antonio José Molina de la Torre; Aurelio Barricarte; Adonina Tardon; Antonio Camacho; Rosana Peiro-Perez; Rafael Marcos-Gragera; Montse Muñoz; Maria Jesus Michelena-Echeveste; Luis Ortega Valin; Marcela Guevara; Gemma Castaño-Vinyals; Nuria Aragonés; Manolis Kogevinas; Marina Pollán; Javier Llorca
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.